[go: up one dir, main page]

WO2017155375A3 - Procédé de prédiction du risque éventuel d'infection de fœtus intra-utérin par le vih par une femme enceinte infectée par le vih dans les six premiers mois de la grossesse - Google Patents

Procédé de prédiction du risque éventuel d'infection de fœtus intra-utérin par le vih par une femme enceinte infectée par le vih dans les six premiers mois de la grossesse Download PDF

Info

Publication number
WO2017155375A3
WO2017155375A3 PCT/LV2016/000003 LV2016000003W WO2017155375A3 WO 2017155375 A3 WO2017155375 A3 WO 2017155375A3 LV 2016000003 W LV2016000003 W LV 2016000003W WO 2017155375 A3 WO2017155375 A3 WO 2017155375A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
predicting
mother
risk
intrauterine fetus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/LV2016/000003
Other languages
English (en)
Other versions
WO2017155375A2 (fr
Inventor
Jelena EGLĪTE
Diāna KASJKO
Vladislavs JASINSKIS
Elvīra HAGINA
Inga JANUŠKEVIČA
Gunta STŪRE
Baiba ROZENTĀLE
Jelena STOROŽENKO
Ludmila VĪKSNA
Original Assignee
Rīgas Stradiņa Universitāte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rīgas Stradiņa Universitāte filed Critical Rīgas Stradiņa Universitāte
Publication of WO2017155375A2 publication Critical patent/WO2017155375A2/fr
Publication of WO2017155375A3 publication Critical patent/WO2017155375A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5434—IL-12
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne la médecine, plus précisément les maladies infectieuses et les études génétiques moléculaires, et peut être utilisée pour prévoir le risque possible d'infection d'un fœtus intra-utérin par le VIH. L'invention concerne un procédé de prévision du risque éventuel d'infection de fœtus intra-utérin par le VIH par une femme enceinte infectée par le VIH. L'objectif est de détecter des mutations dans des gènes des cytokines TNFα, IL2, IL4, IL12β, IL10 et les teneurs en IL2 et IL12 dans le sérum sanguin d'une femme enceinte infectée par le VIH.
PCT/LV2016/000003 2016-03-09 2016-07-19 Procédé de prédiction du risque éventuel d'infection de fœtus intra-utérin par le vih par une femme enceinte infectée par le vih dans les six premiers mois de la grossesse Ceased WO2017155375A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LVP-16-14 2016-03-09
LVP-16-14A LV15133B (lv) 2016-03-09 2016-03-09 Ar HIV inficētas mātes intrauterīnas augļa HIV inficēšanās prognozēšanas paņēmiens pirmajos sešos grūtniecības mēnešos

Publications (2)

Publication Number Publication Date
WO2017155375A2 WO2017155375A2 (fr) 2017-09-14
WO2017155375A3 true WO2017155375A3 (fr) 2018-03-08

Family

ID=57136079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/LV2016/000003 Ceased WO2017155375A2 (fr) 2016-03-09 2016-07-19 Procédé de prédiction du risque éventuel d'infection de fœtus intra-utérin par le vih par une femme enceinte infectée par le vih dans les six premiers mois de la grossesse

Country Status (2)

Country Link
LV (1) LV15133B (fr)
WO (1) WO2017155375A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009117122A2 (fr) * 2008-03-19 2009-09-24 Existence Genetics Llc Analyse génétique
BY18123C1 (fr) * 2011-04-25 2014-04-30

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009117122A2 (fr) * 2008-03-19 2009-09-24 Existence Genetics Llc Analyse génétique
BY18123C1 (fr) * 2011-04-25 2014-04-30

Also Published As

Publication number Publication date
WO2017155375A2 (fr) 2017-09-14
LV15133B (lv) 2017-01-20
LV15133A (lv) 2016-06-20

Similar Documents

Publication Publication Date Title
Singh et al. Biosensors for pathogen detection: A smart approach towards clinical diagnosis
Merten et al. Viral vectors for gene therapy and gene modification approaches
Tahmasebi et al. Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2
Lougaris et al. Altered germinal center reaction and abnormal B cell peripheral maturation in PI3KR1-mutated patients presenting with HIGM-like phenotype
WO2016081518A3 (fr) Lymphocytes t gamma delta produits par génie génétique
EP4269601A3 (fr) Cellules t modifiées, leurs procédés de préparation et utilisation
EA201892443A1 (ru) Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови
Villalobos et al. Drug resistance mutations in proviral DNA of HIV-infected patients with low level of viremia
Raghavan et al. Immunogenetics of HIV and HIV associated tuberculosis
WO2017155375A3 (fr) Procédé de prédiction du risque éventuel d'infection de fœtus intra-utérin par le vih par une femme enceinte infectée par le vih dans les six premiers mois de la grossesse
EP4331676A3 (fr) Vaccins viraux
Hwang et al. Are clonal cells circulating in the peripheral blood of myelodysplastic syndrome?: Quantitative comparison between bone marrow and peripheral blood by targeted gene sequencing and fluorescence in situ hybridization
WO2016163764A3 (fr) Préparation stabilisée de variant d'interféron-bêta
Asahina et al. Pustular psoriasis in a patient with Turner syndrome: profile of serum cytokine levels
LV15235A (lv) HIV inficēšanās riska iespēju noteikšanas paņēmiens sievietēm
Soentjens et al. 'Alternative abridged preventive regimens against rabies for children in high endemic countries'
Kayumov et al. Role of polymorphism RS1800629 gene proinflammatory cytokine TNF-α in the development and clinical course of leukemia
Chow et al. Herd protection from the female HPV vaccination programme-Authors' reply
Исамулаева Genetic polymorphism as a risk factor of inflammatory periodontal diseases at patients with gastric ulcer and duodenal ulcer living in the Astrakhan region
Lee et al. Visfatin, breastfeeding, and breast cancer
Bellizzi et al. Human polyomavirus JC presence in chronic inflammatory rheumatic diseases patients treated with anti-TNF-α: evaluation of JC viral loads in urine and plasma samples
Reis et al. Glomerular filtration rate, potentially the Missed link between serum uric acid and erectile dysfunction
Sultanova Role of ronkoleykin in the immunocorrecion of disbalance in cytokine status of children with bronchial astma
Zerem et al. What is the optimal treatment for hepatic abscess and infected biloma?
Huseynova et al. Comparative evaluation of cytokines and immune status indicators in intestinal-parasitic infections

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16893710

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 16893710

Country of ref document: EP

Kind code of ref document: A2